Approved treatments for osteoporosis and what's in the pipeline

Drug Benefit Trends

Volumn 22, Issue 4, 2010, Pages 121-124

  Davis, Stacy ^a   Sachdeva, Alok ^a   Goeckeritz, Bruce ^a   Oliver, Alyce ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; ARZOXIFENE; BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; COLLAGEN; CREATININE; DENOSUMAB; ESTROGEN; IBANDRONIC ACID; LASOFOXIFENE; ODANACATIB; OSTEOCALCIN; PARATHYROID HORMONE DERIVATIVE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; STRONTIUM; TIBOLONE; UNCLASSIFIED DRUG; VITAMIN D; ZOLEDRONIC ACID; ZT 031;

ALCOHOL CONSUMPTION; ARTHRALGIA; ARTICLE; BONE DENSITY; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; CREATININE CLEARANCE; DIET; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTROGEN THERAPY; EXERCISE; FRAGILITY FRACTURE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPOGONADAL OSTEOPOROSIS; JAW OSTEONECROSIS; LIFESTYLE MODIFICATION; MORBIDITY; MORTALITY; MYALGIA; OSTEOPOROSIS; OSTEOSARCOMA; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; RECOMMENDED DRUG DOSE; RISK; SMOKING CESSATION; SPINE RADIOGRAPHY;

EID: 77953549581     PISSN: 10805826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. The NTH Osteoporosis and Related Bone Diseases National Resource Center, http://www.niams.nih.gov/bone. Accessed March 17, 2010.
2. Binkley N, Bilezikian JP, Kendler DL, et al; International Society for Clinical Densitometry. Official positions of the International Society for Clinical Densitometry and Executive Summary of the 2005 Position Development Conference. J Clin Densitom. 2006;9:4-14.
3. Cosman F, Dempster DW, Gass ML, et al. Optimizing treatment decisions in osteoporosis: the what, when, and how of treatment. Curr Med Evidence. 2009;2(5).
4. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington DC: National Osteoporosis Foundation; 2008. http://www.nof.org. Accessed March 22, 2010.
5. Cosman F, Dempster DW, Gass ML, et al. Clinical and mechanistic insights into novel agents in development for osteoporosis. Curr Med Evidence. 2009;2(5).
6. Rossini M, Viapiana O, Gatti D, Adami S. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review. Clin Ther. 2009;31:1497-1510.
7. Boonen S, Vanderschueren D, Venken K, et al. Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance. J Intern Med. 2008;264:315-332.
8. Khosla S, Burr D, Cauley J, et al; American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22: 1479-1491.
9. Loke YK, Jeevanantham V, Singh S. Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Drug Saf. 2009;32:219-228.
10. Qiao Z. Monitoring the effects of treatment of osteoporosis - is it worthwhile? The Osteoporosis Report. 2009;1(1):19-22. http://www. theosteoporosisreport.com.
11. Black DM, Schwartz AV, Ensrud KE, et al; FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296: 2927-2938.
12. Rosen HN. Bisphosphonates in the management of osteoporosis in postmenopausal women. UpToDate for patients. http://www.uptodate.com/online. Accessed March 17, 2010.